Elmind Capital LP Makes New $17.06 Million Investment in CytomX Therapeutics, Inc. $CTMX

Posted by Brenda Bartman on Aug 26th, 2026

Elmind Capital LP purchased a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 4,550,000 shares of the biotechnology company’s stock, valued at approximately $17,062,500. CytomX Therapeutics accounts for about 0.0% of Elmind Capital LP’s portfolio, making the stock its 9th biggest position. Elmind Capital LP owned about 2.09% of CytomX Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the company. Wells Fargo & Company MN increased its stake in shares of CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of CytomX Therapeutics in the fourth quarter valued at $35,000. Lido Advisors LLC bought a new stake in CytomX Therapeutics during the 1st quarter valued at $49,000. May Hill Capital LLC purchased a new position in shares of CytomX Therapeutics during the fourth quarter worth $46,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in CytomX Therapeutics during the first quarter worth approximately $52,000. Institutional investors own 67.77% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on CTMX. Wall Street Zen lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 23rd. Zacks Research cut CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. JPMorgan Chase & Co. lowered their target price on CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating for the company in a research note on Thursday, August 13th. Weiss Ratings restated a “sell (d)” rating on shares of CytomX Therapeutics in a research report on Tuesday, June 16th. Finally, Guggenheim reduced their target price on shares of CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, CytomX Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $11.90.

Check Out Our Latest Report on CytomX Therapeutics

CytomX Therapeutics Price Performance

NASDAQ CTMX traded down $0.17 on Friday, hitting $3.25. 1,565,458 shares of the company’s stock were exchanged, compared to its average volume of 4,846,738. CytomX Therapeutics, Inc. has a fifty-two week low of $1.90 and a fifty-two week high of $8.21. The firm’s 50-day moving average price is $3.45 and its two-hundred day moving average price is $4.04. The firm has a market cap of $708.17 million, a price-to-earnings ratio of -6.50 and a beta of 2.12.

CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The business had revenue of $1.42 million for the quarter, compared to analyst estimates of $12.39 million. CytomX Therapeutics had a negative return on equity of 38.46% and a negative net margin of 435.21%. On average, research analysts predict that CytomX Therapeutics, Inc. will post -0.4 earnings per share for the current fiscal year.

CytomX Therapeutics Company Profile

(Free Report)

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.